氯法拉滨。百奥维达/依列克斯公司。

Clofarabine. Bioenvision/ILEX.

作者信息

Sternberg Alexander

机构信息

Academic Department of Haematology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK.

出版信息

Curr Opin Investig Drugs. 2003 Dec;4(12):1479-87.

PMID:14763136

Abstract

Clofarabine is a purine nucleoside antimetabolite under development by Bioenvision (under license from the Southern Research Institute) and ILEX for the potential treatment of solid tumors, acute myelogenous leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic and chronic lymphocytic leukemia. In September 2003, Bioenvision initiated a phase II trial in Europe in pediatric acute lymphoblastic leukemia, and in October 2003, ILEX submitted the first part of a rolling NDA to the FDA for the treatment of acute leukemia in children.

摘要

氯法拉滨是一种嘌呤核苷抗代谢物，由Bioenvision（根据南方研究所的许可）和ILEX公司正在开发，用于潜在治疗实体瘤、急性髓性白血病、非霍奇金淋巴瘤、急性淋巴细胞白血病和慢性淋巴细胞白血病。2003年9月，Bioenvision在欧洲启动了一项针对儿童急性淋巴细胞白血病的II期试验，2003年10月，ILEX向美国食品药品监督管理局提交了滚动新药申请的第一部分，用于治疗儿童急性白血病。